All

Landmark Diabetes Prevention Jun 7, 2026

Diabetes Prevention Program: Lifestyle Intervention Reduces Type 2 Diabetes Incidence by 58% in High-Risk Adults

The Diabetes Prevention Program demonstrated that intensive lifestyle intervention reduces type 2 diabetes incidence by 58% with a NNT of 6.9 over 2.8 years in high-risk adults, outperforming metformin which reduced incidence by 31%, establishing structured lifestyle modification as the primary preventive strategy for pre-diabetes and the evidence base for national prevention programmes.

Landmark Cardiovascular Outcomes Jun 7, 2026

VADT: Intensive Glucose Control Provides No Cardiovascular Benefit in Long-Standing High-Risk Type 2 Diabetes

VADT demonstrated that intensive glucose control achieving a median HbA1c of 6.9% did not significantly reduce cardiovascular events or mortality in veterans with long-standing type 2 diabetes and high cardiovascular disease prevalence, completing the ACCORD/ADVANCE/VADT triptych that defined the limits of aggressive glycaemic management in advanced disease.

Landmark Diabetes & Glycaemic Control Jun 7, 2026

ADVANCE: Intensive Glucose Control Reduces Nephropathy by 21% in High-Risk Type 2 Diabetes Without Mortality Harm

ADVANCE demonstrated that intensive glucose control targeting HbA1c below 6.5% using a gliclazide-based strategy reduces nephropathy by 21% and the microvascular composite by 14% in high-risk type 2 diabetes, without the mortality hazard observed in ACCORD, providing important context for how glycaemic targets and treatment strategies interact with safety outcomes.

Landmark Cardiovascular Outcomes Jun 7, 2026

ACCORD: Targeting HbA1c Below 6.0% Increases Mortality by 22% in High-Risk Type 2 Diabetes

ACCORD demonstrated that targeting an HbA1c below 6.0% in high-risk type 2 diabetes patients with established cardiovascular disease increased all-cause mortality by 22% without significantly reducing cardiovascular events, establishing that very intensive glycaemic targets are harmful in this population and reshaping international guidelines to mandate individualised HbA1c targeting.

Landmark Cardiovascular Outcomes Jun 7, 2026

Steno-2: Multifactorial Intervention Reduces All-Cause Mortality by 46% and Cardiovascular Events by 59% in High-Risk Type 2 Diabetes

Steno-2 demonstrated that intensive multifactorial risk factor intervention targeting glycaemia, blood pressure, lipids, and lifestyle simultaneously reduces all-cause mortality by 46% and cardiovascular events by 59% over 13.3 years in type 2 diabetes with microalbuminuria, providing the defining evidence for comprehensive cardiovascular risk management in high-risk type 2 diabetes.

Landmark Cardiovascular Outcomes Jun 7, 2026

UKPDS 38: Tight Blood Pressure Control Reduces Stroke by 44% and Diabetes Complications by 24–37% in Type 2 Diabetes

UKPDS 38 demonstrated that tight blood pressure control targeting below 150/85 mmHg reduces stroke by 44%, diabetes-related endpoints by 24%, and microvascular complications by 37% in hypertensive type 2 diabetes over 8.4 years, establishing blood pressure control as a therapeutic target of at least equal macrovascular importance to glycaemic management.

Landmark Cardiovascular Outcomes Jun 7, 2026

UKPDS 34: Metformin Reduces Mortality by 36% in Overweight Type 2 Diabetes — Establishing First-Line Standard of Care

UKPDS 34 demonstrated that metformin reduces diabetes-related endpoints, death, and all-cause mortality by 32–42% in overweight patients with newly diagnosed type 2 diabetes, with superior cardiovascular outcomes compared with sulphonylurea or insulin, establishing metformin as the preferred first-line pharmacological therapy for type 2 diabetes for the subsequent three decades.

Landmark Diabetes & Glycaemic Control Jun 7, 2026

UKPDS 33: Intensive Glucose Control Reduces Microvascular Complications by 25% in Newly Diagnosed Type 2 Diabetes

UKPDS 33 established that intensive blood-glucose control with sulphonylurea or insulin reduces microvascular complications by 25% in newly diagnosed type 2 diabetes over 10 years with a 0.9% HbA1c differential, confirming the glucose hypothesis for type 2 diabetes microvascular disease and forming the foundational evidence for tight glycaemic management from diagnosis.

Landmark Cardiovascular Outcomes Jun 7, 2026

EDIC: Metabolic Memory — Early Intensive Therapy Reduces Cardiovascular Events by 42–57% Over 17 Years in Type 1 Diabetes

The EDIC study demonstrated that 6.5 years of intensive glycaemic therapy during the DCCT reduced cardiovascular events by 42–57% over 17 years of follow-up despite subsequent HbA1c convergence between groups, establishing the concept of metabolic memory and providing foundational evidence that early intensive glycaemic control produces durable cardiovascular protection extending decades beyond the intervention period.

Landmark Diabetes & Glycaemic Control Jun 7, 2026

DCCT: Intensive Insulin Therapy Reduces Microvascular Complications by 39–76% in Type 1 Diabetes

The Diabetes Control and Complications Trial demonstrated that intensive insulin therapy targeting near-normal blood glucose reduced the risk of developing retinopathy by 76% in primary prevention and slowed progression by 54% in secondary intervention, while also substantially reducing nephropathy and neuropathy, establishing the foundational evidence for tight glycaemic control in type 1 diabetes.